IP Verse

Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator

Patent No. EP3798214 (titled "Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator") was filed by Vertex Pharmaceuticals Incorporated on Oct 6, 2015. The application was issued on Sep 14, 2022.

Patent Summary

Compounds for treating cystic fibrosis (CF) by modulating CFTR chloride channel function. The compounds are CFTR potentiators that increase CFTR activity and anion transport. They can be used alone or in combination with other CFTR modulators to enhance CFTR function. The compounds have structures containing a 6-substituted 3-methylpyridine ring linked to a benzamide or benzoic acid moiety. They can be used as pharmaceuticals to treat CF by improving CFTR function in patients with CFTR mutations.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJun 12, 2023ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3798214

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP20188642A
Filing Date
Oct 6, 2015
Status
Granted And Under Opposition
Aug 12, 2022
Publication Date
Sep 14, 2022
External Links
Slate, Register , Google Patents